Galectin Therapeutics, Inc. (GALT)
3.90
+0.14
(+3.72%)
USD |
NASDAQ |
Oct 02, 16:00
3.85
-0.05
(-1.28%)
After-Hours: 20:00
Galectin Therapeutics Net Income (Quarterly) : -9.113M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.113M |
| March 31, 2026 | -5.046M |
| December 31, 2025 | -5.50M |
| September 30, 2025 | -8.184M |
| June 30, 2025 | -7.521M |
| March 31, 2025 | -9.631M |
| December 31, 2024 | -11.97M |
| September 30, 2024 | -11.22M |
| June 30, 2024 | -12.37M |
| March 31, 2024 | -11.49M |
| December 31, 2023 | -9.997M |
| September 30, 2023 | -10.43M |
| June 30, 2023 | -9.114M |
| March 31, 2023 | -11.53M |
| December 31, 2022 | -10.63M |
| September 30, 2022 | -8.597M |
| June 30, 2022 | -9.613M |
| March 31, 2022 | -9.932M |
| December 31, 2021 | -7.221M |
| September 30, 2021 | -8.52M |
| June 30, 2021 | -8.449M |
| March 31, 2021 | -6.338M |
| December 31, 2020 | -7.852M |
| September 30, 2020 | -5.943M |
| June 30, 2020 | -6.114M |
| Date | Value |
|---|---|
| March 31, 2020 | -3.556M |
| December 31, 2019 | -5.137M |
| September 30, 2019 | -2.784M |
| June 30, 2019 | -2.998M |
| March 31, 2019 | -2.375M |
| December 31, 2018 | -3.05M |
| September 30, 2018 | -2.752M |
| June 30, 2018 | -3.84M |
| March 31, 2018 | -4.258M |
| December 31, 2017 | -2.382M |
| September 30, 2017 | -4.408M |
| June 30, 2017 | -4.508M |
| March 31, 2017 | -4.937M |
| December 31, 2016 | -4.591M |
| September 30, 2016 | -4.526M |
| June 30, 2016 | -5.519M |
| March 31, 2016 | -6.80M |
| December 31, 2015 | -4.671M |
| September 30, 2015 | -5.887M |
| June 30, 2015 | -4.643M |
| March 31, 2015 | -4.826M |
| December 31, 2014 | -3.788M |
| September 30, 2014 | -3.575M |
| June 30, 2014 | -3.429M |
| March 31, 2014 | -5.168M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Mirum Pharmaceuticals, Inc. | -67.23M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 9.113M |
| EPS Diluted (Quarterly) | -0.1393 |
| Enterprise Value | 385.31M |
| Earnings Yield | -11.02% |
| Normalized Earnings Yield | -9.749 |